Relevant for
FixVUE, InSituPlex, U-VUE
Description Overview highlighting the use of the InSituPlex® (ISP) a novel, robust mIF assay technology reliant on conjugating DNA barcodes to antibodies and using sequence-specific DNA-DNA hybridization tolabel antibodies for spatial profiling of immuno-oncology targets in FFPE tumor tissue
Senior Field Applications Scientist, Ultivue
Relevant for
FixVUE, InSituPlex
Description During this webinar, Dr. Ralf Huss from University Hospital in Augsburg discussed how understanding the entire tumor heterogeneity, its immune environment, and contextual relationship requires the spatial quantification of different immune and tumor cells along with the genetic background of the individual cancer.
Ralf Huss is a Professor of Pathology and the managing deputy director of Pathology and Molecular Diagnostics at the University Hospital in Augsburg (Germany), where he also leads the Center for Digital Medicine. He is board-certified in anatomical, experimental, and molecular pathology with more than 30 years of experience in histopathology, immunology, cancer research and oncology.
Associate Director, Scientific Affairs; Senior Scientist, Visiopharm
Relevant for
Collaboration, FixVUE, InSituPlex
Description During this webinar, Dr. Ralf Huss from University Hospital in Augsburg discussed how understanding the entire tumor heterogeneity, its immune environment, and contextual relationship requires the spatial quantification of different immune and tumor cells along with the genetic background of the individual cancer.
Ralf Huss is a Professor of Pathology and the managing deputy director of Pathology and Molecular Diagnostics at the University Hospital in Augsburg (Germany), where he also leads the Center for Digital Medicine. He is board-certified in anatomical, experimental, and molecular pathology with more than 30 years of experience in histopathology, immunology, cancer research and oncology.
Dr. Fabian Schneider is part of Visiopharm’s R&D and Product Management team, responsible for phenotyping products as well as service projects for custom APP development. Fabian has over 10 years of international experience in cancer biology and immuno-oncology, working in academic research labs, clinical research teams and computational pathology groups in both academia and biopharma. Fabian received his Dr phil. nat. in Cell Biology in 2011 from the Johan Wolfgang Goethe University Frankfurt, Germany.
Relevant for
Collaboration, FixVUE, InSituPlex
Description We describe the potential of accurate cellular phenotyping using the InSituPlex technology with fast whole-slide scanning using ZEISS Axioscan 7, an automated slide scanning system for fluorescence and transmitted light applications with modern cameras, a sophisticated focusing method and a powerful imaging software. The compounded effect of integrating these technologies can significantly improve the throughput of immuno-oncology research.
Catherine Benson, Keith Wharton, Gourab Chatterjee, Markus Neumann, Volker Döring and Maël Manesse
Presented at: AACR 2021
Relevant for
Collaboration, FixVUE, InSituPlex
Description During this webinar, Dr. Ralf Huss from University Hospital in Augsburg discussed how understanding the entire tumor heterogeneity, its immune environment, and contextual relationship requires the spatial quantification of different immune and tumor cells along with the genetic background of the individual cancer.
Marie Cumberbatch, Douglas Wood, Christopher Womack, Milan Bhagat, Angela Vasaturo, Mael Manesse and Lorcan Sherry (TriStar, OracleBio)
Relevant for
FixVUE, FlexVUE, InSituPlex, U-VUE
Description Overview highlighting the use of the InSituPlex® (ISP) a novel, robust mIF assay technology reliant on conjugating DNA barcodes to antibodies and using sequence-specific DNA-DNA hybridization tolabel antibodies for spatial profiling of immuno-oncology targets in FFPE tumor tissue
Associate Director, Scientific Affairs Ultivue ;Tissue Hybridization Scientific Lead, Queens University Belfast
Relevant for
FixVUE, InSituPlex
Description During this webinar, Dr. Ralf Huss from University Hospital in Augsburg discussed how understanding the entire tumor heterogeneity, its immune environment, and contextual relationship requires the spatial quantification of different immune and tumor cells along with the genetic background of the individual cancer.
Ralf Huss is a Professor of Pathology and the managing deputy director of Pathology and Molecular Diagnostics at the University Hospital in Augsburg (Germany), where he also leads the Center for Digital Medicine. He is board-certified in anatomical, experimental, and molecular pathology with more than 30 years of experience in histopathology, immunology, cancer research and oncology.
At Queens University Belfast, Matt is the Scientific Lead for Tissue Hybridization and Digital Pathology in the Precision Medicine Centre of Excellence. Matt is responsible for the TH&DP team. Their remit was to deliver academic research studies, clinical trials, and industry projects within the PMC.
Presented at: AACR 2020
Relevant for
Collaboration, FixVUE, InSituPlex
Presented at: AACR 2021
Relevant for
Collaboration, FixVUE, InSituPlex
Description During this webinar, Dr. Ralf Huss from University Hospital in Augsburg discussed how understanding the entire tumor heterogeneity, its immune environment, and contextual relationship requires the spatial quantification of different immune and tumor cells along with the genetic background of the individual cancer.
Presented at: AACR 2021
Relevant for
Collaboration, FixVUE, InSituPlex
Description During this webinar, Dr. Ralf Huss from University Hospital in Augsburg discussed how understanding the entire tumor heterogeneity, its immune environment, and contextual relationship requires the spatial quantification of different immune and tumor cells along with the genetic background of the individual cancer.
Presented at: AACR 2021
Relevant for
FixVUE, InSituPlex
Description During this webinar, Dr. Ralf Huss from University Hospital in Augsburg discussed how understanding the entire tumor heterogeneity, its immune environment, and contextual relationship requires the spatial quantification of different immune and tumor cells along with the genetic background of the individual cancer.
Presented at: AACR 2021
Relevant for
Collaboration, FixVUE, InSituPlex
Description During this webinar, Dr. Ralf Huss from University Hospital in Augsburg discussed how understanding the entire tumor heterogeneity, its immune environment, and contextual relationship requires the spatial quantification of different immune and tumor cells along with the genetic background of the individual cancer.
Presented at: AACR 2021
Relevant for
Collaboration, InSituPlex
Description During this webinar, Dr. Ralf Huss from University Hospital in Augsburg discussed how understanding the entire tumor heterogeneity, its immune environment, and contextual relationship requires the spatial quantification of different immune and tumor cells along with the genetic background of the individual cancer.
Relevant for
Collaboration, FixVUE, InSituPlex
Description Overview highlighting the use of the InSituPlex® (ISP) a novel, robust mIF assay technology reliant on conjugating DNA barcodes to antibodies and using sequence-specific DNA-DNA hybridization tolabel antibodies for spatial profiling of immuno-oncology targets in FFPE tumor tissue
Anne Hellebust, Kyla Teplitz, Katir K Patel, Karan Sharma, Amanda Bares, Mael Manesse, Mark Burton, Bonnie Phillips, Sean Downing and Kate Lillard
Relevant for
Collaboration, FixVUE, InSituPlex
Description Overview highlighting InSituPlex technology coupled to the SLIDEVIEW VS200 scanner to produce high-quality, aligned images of eight targets in FFPE tumor sections
Amanda Bares, Alec De Grand, Douglas Wood and Maël Manesse
Spatial biology
5880
Getting TiME on Your Side: Defining the future of precision medicine with advanced multiplexed immunofluorescence
